Pharmafile Logo
Pharmafocus logo
Advanced Search

Ozurdex

Showing 5 posts of 5 posts found.

Roche logo

NICE signs-off Roche’s Gazyvaro for leukaemia

June 2, 2015
Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia

NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …

News
Rawlins image

Sue NHS to ensure access to drugs, says NICE chief

August 6, 2012
Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology

 The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …

News
Lucentis image

Lucentis not backed by NICE for new licence

November 24, 2011
Sales and Marketing Lucentis, NICE, Novartis, Ozurdex

NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …

News

NICE thumbs up for Allergan’s Ozurdex

June 9, 2011
Sales and Marketing Allergan, BRVO, CVRO, NICE, Ozurdex

In draft guidance NICE has recommended the use of Allergan’s eye treatment Ozurdex.NICE’s final decision on Ozurdex (dexamethasone) is expected …

News

European green light for Allergan’s Ozurdex

May 25, 2010
Sales and Marketing Allergan, CHMP, Ozurdex, macular oedema

European authorities have given the green light for Ozurdex, a treatment for adults with a potentially serious eye disease. Ozurdex …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024